Phase 3
Completed N=11
RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)
Sjogren-Larsson Syndrome
Source: ClinicalTrials.gov NCT03445650 ↗
Enrolled (actual)
11
Serious AEs
0.0%
Results posted
Feb 2023
Primary outcomePrimary: Visual Index Ichthyosis Severity (VIIS) Scaling Score as Assessed by the Investigator in ADX-102 Treated Patients — -0.7 units on a scale
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of ADX-102 1% Topical Dermal Cream in Subjects with Sjögren-Larsson Syndrome (SLS).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Visual Index Ichthyosis Severity (VIIS) Scaling Score as Assessed by the Investigator in ADX-102 Treated Patients |
-0.7 | — |
Eligibility Criteria
Inclusion Criteria
- Subject is aged 3 years or older
- Subject has a genetically-confirmed diagnosis of SLS.
- Subject has active ichthyosis that is Grade 2 or higher on the Visual Index Ichthyosis Severity (VIIS) score.
- Females of child-bearing potential: Negative pregnancy test at Screening and Baseline Visits.
Exclusion Criteria
- Subject has evidence of a serious active infection.
- Systemic or topical retinoids or other topical medications, not including emollients, within the past 30 days Baseline Visit 1.
- Subject has received an investigational systemic or topically administered drug within the past 30 days prior to Baseline Visit 1.
- Subject is currently receiving immunosuppressive therapy, including intermittent or low-dose systemic corticosteroids.
- Subject has a known allergic reaction to any ingredients of study drug formulation.
- Subject has any clinically significant laboratory test abnormalities or a history of any other condition that, in the opinion of the Investigator, could compromise the subject's ability to comply with the protocol or that could compromise the subject's safety or the interpretation of the study results.
Data sourced from ClinicalTrials.gov (NCT03445650). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.